Trials / Completed
CompletedNCT00123565
Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction
A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,257 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hexadecasaccharide (SR123781A) |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2005-07-25
- Last updated
- 2008-08-21
Locations
18 sites across 18 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, France, India, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00123565. Inclusion in this directory is not an endorsement.